AACHEN, Germany and
GOTHENBURG, Sweden, Dec. 14, 2018 /PRNewswire/ -- Grünenthal and
OnDosis announced today that they have entered into an exclusive
collaboration to develop the OnDosis' technology for prescription
medicines in all pain related indications. The agreement also
entails an option for Grünenthal to an exclusive worldwide license
to the technology in these indications. The handheld device enables
individualised dosing of oral medicines in micro units, provides
support for patient compliance, can be combined with digital
solutions and thus significantly improves patients' safety. The
agreement with Grünenthal, a leading pain specialist, is the first
partnering deal for life science startup OnDosis on their
innovative technology. While this agreement covers the indication
area pain; other focus areas of OnDosis, like ADHD and
immunosuppression, remain available for further cooperation with
third parties.
"We are thrilled to enter our first partnering agreement with
the leading pain company Grünenthal to further explore how our
technology can generate added value for pain patients. This
agreement is obviously an import milestone and a clear evidence of
the interest in our technology," says Martin Olovsson, CEO of OnDosis.
"We constantly strive to develop innovative, convenient and safe
solutions for patients. Beyond individualised dosing, OnDosis can
serve as an interface to digital applications that may further
support a holistic approach to pain management in the future. It's
a perfect strategic fit and complements our portfolio of pain
medicines", says Gabriel Baertschi,
CEO of Grünenthal.
As part of the agreed terms, OnDosis will receive a technology
access fee in addition to later development and regulatory
milestone payments, as well as sales related royalties.
Financial terms of the agreement were not disclosed.
About Grünenthal
Grünenthal is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a € 2 bn
company. We are a fully integrated research & development
company with a long track record of bringing innovative pain
treatments and state-of-the-art technologies to patients. By
sustainably investing in our R&D above the industrial average,
we are strongly committed to innovation.
Grünenthal is an independent, family-owned company
headquartered in Aachen, Germany.
We are present in approx. 30 countries with affiliates in
Europe, Latin America and the US. Our products are
sold in more than 100 countries and approx. 5,200 employees are
working for Grünenthal worldwide. In 2017, Grünenthal achieved
revenues of approx. € 1.3 bn.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal
Group
Twitter: @grunenthalgroup
Instagram: gruenenthal
About OnDosis
Swedish life science company OnDosis has developed a proprietary
technology to deliver flexible and individualised dosing of oral
medicines. By integrating medicines with intelligent dosing and
digital capabilities in a handheld device, OnDosis offers a new way
to take oral medicines – in micro units. Individualised, intuitive
and intelligent. Initial focus areas are pain, ADHD and
immunosuppression. OnDosis is a spin-out from AstraZeneca and
headquartered in Gothenburg,
Sweden.
More information at www.ondosis.com
Follow us on: LinkedIn: OnDosis
For more information, please contact:
Štěpán
Kráčala
|
Martin
Olovsson
|
Head Global
Communications
|
Chief Executive
Officer
|
Tel.: +49 241
569-1335
|
Tel. +46 (0)76-772
8501
|
Stepan.Kracala@grunenthal.com
|
martin.olovsson@ondosis.com
|
Grünenthal GmbH,
52099 Aachen, Germany
Kerstin Nacken,
Head Editorial Management and Media Relations
Tel.: +49 241
569-2710, Kerstin.Nacken@grunenthal.com
Grünenthal GmbH,
52099 Aachen, Germany
|
OnDosis AB,
Pepparedsleden 1, 431 50 Mölndal, Sweden
|
View original
content:http://www.prnewswire.com/news-releases/grunenthal-and-ondosis-team-up-for-individualised-dosing-of-oral-drugs-in-pain-management-to-increase-patient-safety-300765215.html
SOURCE Grünenthal Group